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The role of immune response is emerging as a key factor in the complex multistep process of cancer. Tumor
microenvironment contains different types of immune cells, which contribute to regulate the fine balance between
anti and protumor signals. In this context, mechanisms of crosstalk between cancer and immune cells remain to
be extensively elucidated. Interestingly, microRNAs (miRNAs) have been demonstrated to function as crucial
regulators of immune response in both physiological and pathological conditions. Specifically, different miRNAs
have been reported to have a role in controlling the development and the functions of tumor-associated immune
cells. This review aims to describe the most important miRNAs acting as critical modulators of immune response in
the context of different solid tumors. In particular, we discuss recent studies that have demonstrated the
existence of miRNA-mediated mechanisms regulating the recruitment and the activation status of specific
tumor-associated immune cells in the tumor microenvironment. Moreover, various miRNAs have been found to
target key cancer-related immune pathways, which concur to mediate the secretion of immunosuppressive or
immunostimulating factors by cancer or immune cells. Modalities of miRNA exchange and miRNA-based
delivery strategies are also discussed. Based on these findings, the modulation of individual or multiple miRNAs
has the potential to enhance or inhibit specific immune subpopulations supporting antitumor immune
responses, thus contributing to negatively affect tumorigenesis. New miRNA-based strategies can be developed
for more effective immunotherapeutic interventions in cancer.
Keywords: MicroRNAs, Cancer, Immune System, Immune-related MicroRNAs, Innate Immunity, Adaptive
Immunity, Cancer-Related Immune Response, Anticancer ImmunotherapyBackground
Local immune response has emerged in the last decade
as a key element in the modulation of the multistep
process of cancer development [1]. The connection be-
tween tumor onset and inflammation has been envisaged
after the demonstration that some tumors arise from
sites of chronic inflammation. Moreover, not only some
tumors are infiltrated by both the innate and adaptive
arms of the immune system, but these cells are present
even within tumor microenvironment [2]. Immunity has
been reported to act both as a pro- or anti-tumorigenic
factor depending on the fine-tuned equilibrium between
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filtrating immune cells has the main role to modulate
this immune response, thus positively influencing tumor
development [4]. Among the different molecular players
in the field, microRNAs (miRNAs) have been described
as small non–coding RNA molecules regulating different
physiological and pathological processes, including in-
flammation and cancer [5–7]. The multifaceted role of
miRNAs derives from their mechanism of action, based
on post-transcriptional modulation of multiple genes by
base-pairing to target messenger RNAs (mRNAs) [8].
Mature miRNAs are 18-24 nucleotides long, and their
biogenesis process has been widely studied in the past
years. Briefly, primary miRNA (pri-miRNA) transcripts
are produced in the nucleus by RNA polymerases II or
III and subsequently processed into precursor-miRNAs
(pre-miRNAs) by the RNase III domain of endonuclease
Drosha, complexed with DCGR8 [8]. Pre-miRNAs arele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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exportin 5 nuclear protein (EXP5) in complex with Ran-
GTP unit. The RNase III endoribonuclease Dicer converts
pre-miRNAs into RNA duplexes about 22 nucleotides
long, containing one mature miRNA molecule [9]. This
strand is finally incorporated into the RNA-induced si-
lencing complex (RISC), which is the functional unit
of Argonaute-mediated miRNA/mRNA binding and
regulation [10]. Target sequences are usually located
in the 3’untranslated region (UTR) of mRNAs and the
grade of complementarity determines whether it will
be targeted for degradation (total complementarity) or
translational repression (partial complementarity) [11].
The growing body of literature demonstrating the
importance of miRNAs in tumor onset, progression and re-
sponse to therapy has defined these molecules as potential
cancer biomarkers [12–14]. Different delivery strategies
have been developed suggesting novel promising miRNA-
based therapeutic approaches in order to overcome limits
of current treatment of cancer [15]. Recently, due to the
improvements in delivery systems, miRNA-targeting drugs
entered into human clinical trials and the first results about
the efficacy of this therapy is expected to be presented soon
[16, 17]. In the past decades, the importance of miRNAs in
the modulation of normal and pathological immune func-
tion has been shown in various studies in which deregula-
tion of miRNAs was demonstrated to characterize diseases
associated with excessive or uncontrolled inflammation
[18]. There is an increasing number of studies directed to
investigate miRNA-immunity-cancer connection and all
these new data need to be comprehensively understood
for novel therapy applications [19, 20]. Specifically, the
mechanisms of miRNA exchange between cancer and
immune cells have to be further explored and clarified
in a tumor context-dependent manner. Exosomes have
been demonstrated to represent vehicles of this miRNA
transport within tumor microenvironment and recently
also in circulation of cancer patients [21]. This review aims
to summarize the most important miRNAs as regulators
of immune cells (immune-related miRNAs) and to deeply
discuss their role in modulating crucial checkpoints of
cancer-related immune response in different types of solid
tumors. An extensive understanding of effects of these
immune-related miRNAs in cancer will very likely allow
to identify specific miRNAs as potential targets for cancer
immunotherapy.
The role of immune response in cancer
The human immune system has developed as a complex
network of pathways regulating the response to pathogens.
Innate immunity provides the initial defense against patho-
genic infections, while its propagation leads to the activa-
tion of adaptive immune response. At this stage, adaptive
immune cells sustain an extremely versatile mechanism ofhost organism defense in response to the exposure to a
known antigen and/or to the reinfection with the same
pathogen. In the context of cancer, immunity has clearly
emerged as crucial biological event that contributes to the
complex process of tumor development [22]. The patho-
genesis of ∼ 15–20 % of human tumors is linked to
infection-driven inflammation and interestingly, the pres-
ence of an inflammatory component characterizes the
microenvironment of some tumors that are not causally
linked to pathogens [23]. Two general molecular and cel-
lular pathways have been proposed to describe the inter-
action between inflammation and cancer: the intrinsic
pathway and the extrinsic one [23]. The intrinsic pathway
which consists in a series of genetic events (e.g. activation
of oncogenes, inactivation of tumor suppressor genes,
different genetic aberrations) causing neoplastic trans-
formation, initiates the induction of inflammation-related
programs which influence the development of an inflam-
matory microenvironment (e.g. papillary thyroid carcin-
omas, breast cancers). On the other hand, the extrinsic
pathway is driven by inflammatory leukocytes and soluble
mediators that sustain inflammatory conditions increasing
cancer risk (e.g. colon, prostate, pancreas cancers). All
these pathways converge in the first activation of pro-
inflammatory transcription factors in cancer cells and
in their consequential production of inflammatory me-
diators (cytokines, chemokines, cyclooxygenase-2, and
prostaglandins) [24]. Immune cells of innate system, such
as macrophages, myeloid-derived suppressor cells, mast
cells, eosinophils and neutrophils, are the first one to be
recruited upon inflammation, and their activation contrib-
utes to reinforce the pro-inflammatory milieu [25]. The
additional secretion of inflammatory mediators leads to
the re-induction of the same pro-inflammatory pathways
in cancer cells [23]. Independently of the cause that triggers
inflammation, these immune signals present in the tumor
microenvironment play a crucial role in all stages of
cancer evolution, from initiation to metastasis. Indeed,
an effective immune response ensues from the harmo-
nious collaboration between innate and adaptive im-
mune system, with the negative feedback of immune
checkpoints and immunosuppressive mechanisms. On
the other hand, immune response may exert either
pro- or anti-tumorigenic effects on tumor microenviron-
ment. A robust body of literature demonstrates that both
innate and adaptive immunity are able to execute their
role to achieve immunosurveillance, eliminating nascent
tumors through the recognition of tumor neo-antigens as
non-self [26]. On the contrary, following changes occur-
ring in malignant cell populations or in host immune re-
sponse, the immune system can fail to eliminate all cancer
cells and tumors with reduced immunogenicity may
escape the immune attack [27]. This dynamic balance
between host-protective and tumor-promoting functions
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the concept of cancer immunoediting, the process re-
sponsible for both eliminating tumors and modulating
the immunogenic phenotypes of tumors that arise in
immunocompetent hosts [26]. In conditions of equilib-
rium, immune system can induce a state of functional
dormancy in cells, which can evade from this form of
immune-mediated latent tumor through different
strategies that allow them to proliferate [26, 28–33]. In
established tumors, the escape from immunosurveillance
occurs through different mechanisms, either at cancer
(e.g. antigen loss, immunogenic tolerance) or immune cell
level (e.g. T-cell activation inhibition) [34, 35]. In this
second case, the cancer cells immersed in a local immuno-
suppressed microenvironment are required to mediate the
inhibition of effector immune cells, such as T cells, natural
killer cells (NK) or dendritic cells and the recruitment of
immunosuppressive cells (regulatory T cells and myeloid-
derived suppressor cells). Therefore, the heterogeneous
composition of tumor microenvironment in terms of
immune cell type has the potential to define a pro or an
antitumor milieu [36]. Indeed, the presence of tumor-
infiltrating lymphocytes (TILs) in human tumors has been
described as a prognostic factor, supporting the evidence
of immunoediting in this context [37]. Higher frequency
of T cells, NK cells and natural killer T (NKT) cells have
been correlated with better prognosis in patients with
different types of cancer types [38–43]. Specifically, signifi-
cant association between different subsets of T cells and
clinical response have been found in cancer patients. In
particular, a positive effect has been ascribed to CD8+ T
cytotoxic (CTL), CD4+ T helper 1 (TH1) and T follicular
helper (TFH) cells, as opposed to the negative role assigned
to CD4+ regulatory T (TREG), T helper 2 (TH2) and T
helper 17 (TH17) cells [44]. In particular, high ratios of
CD4+/CD8+ and TH2/TH1 lymphocyte markers have been
associated with poor prognosis specifically in breast cancer
[45]. Among immune cells of myeloid origin, tumor-
associated macrophages (TAMs) represent the most abun-
dant cell component of tumor microenvironment, playing
an important role in cancer development [46]. Two main
different subsets of TAMs have been distinctively de-
scribed according to their gene expression profiles and
pattern of secreted molecules [47]. The natural plasticity of
TAMs allows them to easily alter their phenotype during
tumor development, converting from a pro-inflammatory
(M1-like) form at early stages of tumor to a pro-angiogenic/
immunosuppressive (M2-like) form during later phases of
tumor progression (angiogenesis, invasion and metastasis)
[48]. Several human tumors are mostly characterized by the
presence of TAMs with M2-like phenotype [49, 50], while
the presence of high levels of either M2- or M1- like TAMs
has been identified as a poor prognostic factor in diverse
solid tumors [51, 52]. However, understanding of the exactrole of each TAM subset in cancer needs further investiga-
tion. Similarly, neutrophils have been demonstrated to exert
both antitumor and protumor activities, including the
sustainment of T cell responses and the promotion of
angiogenesis and metastasis [46]. In addition, myeloid-
derived suppressor cells (MDSCs) represent another com-
ponent of TILs with multiple immunosuppressive functions
on both innate and adaptive cells [53]. On the contrary,
dendritic cells (DCs) play an important role as antigen pre-
senting cells (APCs), which contribute to mount antitumor
CTL immune response [54, 55]. Therefore, the immune-
related nature of tumor microenvironment is very complex
and depends on finely regulated interactions between cells
[56]. This continuous crosstalk between tumor-infiltrating
immune cells and cancer cells need to be extensively stud-
ied in order to define mechanisms underlying immunosur-
veillance and tumor immune escape.
MicroRNAs as regulators of cancer-related immunity
in solid tumors
It has been widely demonstrated that differential expression
patterns of miRNAs are associated with several human
pathologies, including cancer in all its stages [57–59]. To
date, miRNAs have been classified either as oncogenic (e.g.
miR-155, miR-17-5p or miR-21), or having a tumor sup-
pressor role (e.g. miR-34, miR-15a, let-7) [60–64]. Deregu-
lation of a single miRNA or distinctive miRNA profiles
have been correlated with survival, clinical outcome
and response to therapy in various solid tumors [65–69].
Interestingly, recent studies have also correlated aberrant
expression of crucial proteins related to miRNA biogen-
esis, with poor outcome [70]. Moreover, miRNAs are im-
portant regulators of both innate and adaptive immunity,
controlling the maintenance and the development of im-
mune progenitors as well as the differentiation and the
functions of mature immune cell (Table 1) [71–74].
Therefore, the complexity of mechanisms underlying the
connection between cancer and immunity has led to in-
vestigate miRNAs as additional key molecular players.
Since specific miRNAs are essential for proper immune
cell functioning, it is not surprising that aberrations in ex-
pression of immune-related miRNAs can lead to an al-
tered antitumor immune response and contribute to
cancer development [75, 76]. Indeed, some miRNAs with
validated oncogenic or antitumor properties have shown
the potential to exert a modulation of immune cell activity
in the tumor microenvironment [20]. A large body of lit-
erature has reported different mechanisms by which single
immune-related miRNAs have a double role in cancer de-
velopment and immunity by modulating both immune
and non-immune targets (Table 2). In the next subsec-
tions we are going to investigate the most relevant miR-
NAs with immunomodulatory effects, which can function
as a bridge between immune response and cancer.
Table 1 MicroRNAs involved in Innate and Adaptive Immune System Functions
Cell lineage Cellular process MicroRNAs
Immune cell progenitors
Hematopoietic stem cells Cell maintenance let-7ea, miR-29a, miR-99ba, miR-125a, miR-126, miR-212/132 cluster
Multipotent progenitors Cell development miR-10 family, miR-126, miR-196b, miR-221/222
Common myeloid progenitors Cell development miR-17, miR-24, miR-126, miR-128, miR-155, miR-181a
Common lymphoid progenitors Cell development miR-126, miR-128, miR-146, miR-181a
Granulocyte–macrophage progenitors Cell development miR-16, miR-103, miR-107
Macrophage progenitors Cell development miR-17-5p, miR-20a, miR-106a
Granulocyte progenitors Cell development miR-223
Erythroid precursors Cell development miR-155, miR-221/222
Megakaryocyte precursors Cell development miR-10a/b, miR-17, miR-20, miR-126
Innate immunity
Monocytes Cell differentiation miR-17-5p, miR-20a, miR-21, miR-106a, miR-155, miR-196b, miR-223, miR-338, miR-342, miR-424
Cell activation miR-155, miR-424
Dendritic cells Cell differentiation miR-21, miR-34a
Cell function miR-10a, miR-148/152, miR-155, miR-223
Macrophages Cell differentiation miR-15a, miR-16, miR-19a-3p, miR-21, miR-107, miR-146a, miR-424
Cell function Let-7, miR-9, miR-21, miR-101, miR-125b, miR-146a, miR-147, miR-155, miR-187, miR-212/132 cluster,
miR-378, miR-487b, miR-1224
Cell polarization let-7c, let-7f, miR-9, miR-21, miR-33, miR-101, miR-124, miR-125, miR-146, miR-147, miR-155, miR-187,
miR-223, miR-342, miR-378, miR-511
Granulocytes Cell differentiation miR-15a, miR-21, miR-27, miR-196b, miR-223
Cell function miR-223
Neutrophils Cell function miR-223
MDSCs Cell function miR-494, miR-17-5p/20a
Megakaryocytes Cell differentiation miR-10a, miR-130a, miR-146a, miR-150, miR-155, miR-223
Erythrocytes Cell differentiation miR-15a, miR-16, miR-24, miR-144, miR-150, miR-155, miR-221/222 cluster, miR-223, miR-451
Natural killer cells Cell differentiation miR-150, miR-181a/b
Cell function miR-15/16, miR-27a, miR-29, miR-30c-1, miR-30e, miR-155, miR-223, miR-378
Adaptive immunity
B cells Cell differentiation miR-17/92 cluster, miR-23a, miR-34a, miR-142, miR-150, miR-155, miR-181 family, miR-212/132 cluster
Cell activation miR-9, miR-17/92 cluster, miR-30, miR-125b, miR-155, miR-181b, miR-223
Plasma cells Cell differentiation miR-148a












Table 1 MicroRNAs involved in Innate and Adaptive Immune System Functions (Continued)
Cell activation miR-155, miR-181a, miR-182, miR-214
T helper cells Cell differentiation miR-125b, miR-150
Cell function miR-182, miR-214, miR-297, miR-669c
T helper 1 cells Cell differentiation miR-17/92 cluster, miR-29, miR-146a, miR-148a, miR-155, miR-210, miR-326
T helper 2 cells Cell differentiation miR-21, miR-27, miR-28
Cell function miR-155
T cytotoxic cells Cell differentiation Let-7f, miR-15b, miR-16, miR-17/92 cluster, miR-21, miR-139, miR-142, miR-150, miR-155, miR-342
Cell function miR-17/92 cluster, miR-21, miR-29, miR-23a, miR-24, miR-27a, miR-30b, miR-130/301, miR-139, miR-146a,
miR-150, miR-155, miR-214
T regulatory cells Cell differentiation miR-17/92 cluster, miR-10, miR-99a/miR-150, miR-155
Cell function miR-142-3p, miR-146a, miR-155
T helper 17 cells Cell differentiation miR-10a, miR-19b, miR-17, miR-155, miR-210, miR-212/132 cluster, miR-301, miR-326
T follicular helper cells Cell differentiation miR-10a, miR-17/92 cluster
The most relevant miRNAs are in bold. MDSCs, Myeloid-Derived Suppressor Cells
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The differentiation and the activation of different tumor-
associated immune cells have been described to be
dependent on expression of specific miRNAs (Fig. 1)
[77, 78]. In particular, deregulation of various miRNAs
has been identified to affect monocyte-macrophage lineage
maturation [79]. Members of miR-17/92 and miR-106a/92
clusters (miR-17-5p, miR-20a, and miR-106a) have been
demonstrated to negatively regulate monocyte commitment
by targeting Runt-related transcription factor 1 (RUNX1)
[80]. Interestingly, modulation of miR-155, miR-125a/b,
miR-146a, miR-21, and let-7e have been shown to beFig. 1 Schematic representation of microRNA regulation in immune cell de
as important regulators of both innate and adaptive immunity, including d
relevant miRNAs are included in the figure. The miRNAs in red boxes are
arrows, as well as the activity of cells in the immune system (full explana
cell development or function. HSC: Hematopoietic Stem Cell; CMP: Comm
MEP: Megakaryocyte-Erythrocyte Progenitor; CLP: Common Lymphoid Pro
Negative; DP: Double Positive; SP: Single Positivecrucial for macrophage differentiation and activation
into different phenotypes [81]. Specifically, the upregu-
lation of these miRNAs have been observed to occur in
macrophages after activation of Toll-like receptor (TLR)
signaling and to sustain (i.e. miR-155, miR-125a/b) or re-
press (i.e. miR-146a, let-7e) pro-inflammatory M1- like
TAM activation [79]. In the context of macrophage cell
functions, miR-146a and miR-155 are also the two most
well characterized miRNAs regulating immune response
mediated by these cells [76]. These two miRNAs act as me-
diators of inflammatory stimuli with opposite effects on
inflammatory response, miR-146a as negative and miR-155velopment and activity. MiRNAs have been demonstrated to function
ifferentiation and functions of different immune cell subsets. The most
involved in regulating the developmental transition indicated by the
tion in text). *MicroRNAs involved in negative regulation of immune
on Myeloid Progenitor; GMP: Granulocyte–Monocyte Progenitor;
genitor; DC: Dendritic cell; aDC: activated Dendritic Cell; DN: Double
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ect targeting of IRAK1 and TRAF6, and SOCS1 and BCL6,
respectively [82, 83]. However, this gene network is a part
of a bidirectional mechanism in which inflammatory path-
ways are able to modulate miR-146a and miR-155 expres-
sion, and in turn innate immune response [83–86]. Along
with TAMs, NK cells are another key component of the in-
nate immune response and their differentiation has re-
ported to be determined by miR-150 and miR-181a/b
expression level [87]. In addition to tumor-associated innate
immune cells, miRNAs have been found to regulate cell dif-
ferentiation and functions of different T cell subsets (Fig. 1).
Specifically, T helper effector differentiation has been found
to be regulated by miR-155 expression in favor of TH1
phenotype, by miR-326 in promoting Th17 differentiation,
and by miR-10a and miR-17-92 cluster regulating T follicu-
lar helper maturation [88–90]. In the lineage of CTL cells,
the maturation and the activation of cells into effector or
memory cell subsets have been demonstrated to be pro-
moted by different miRNAs, including miR-17/92, miR-21,
miR-30b and miR-155 [91]. On the contrary, miR-130/301
and miR-146a have displayed inhibiting effects on CTL im-
mune responses [91]. miRNA roles have been also eluci-
dated in Treg cell biology, with particular attention to miR-
142-3p, miR-146a and miR-155 for cell function [92, 93].
All these infiltrating inflammatory cells are recruited
to the tumor microenvironment and their activation can
be modulated by molecular signals produced by stromal
and malignant cells [94]. In this context, distinctive
miRNA-mediated mechanisms have been identified in
different models of cancer (Table 2). In breast cancer
miR-19a-3p has been reported to regulate the switch of
TAMs from a M2-like phenotype into M1-like macro-
phages by targeting the Fra-1 proto-oncogene and other
genes of its downstream signaling pathway (VEGF, STAT3
and pSTAT3), and to contribute to the inhibition of metas-
tasis development [95]. In particular, Fra-1 has been already
demonstrated to have a key role in the polarization of
TAMs from the M1- to the M2-like phenotype [96]. Specif-
ically, in the Balb/c mouse model, in vivo miR-19a-3p intra-
tumoral injection has been found to both decrease the
population of M2-like TAMs and inhibit lung metastasis of
4 T1 breast cancer cell-derived tumors [95]. Similarly, the
miR-23a/27a/24-2 cluster has been demonstrated to
mediate macrophage polarization and to contribute to
tumor progression in breast cancer [97]. These studies
support the concept that the modulation of the expression
of single miRNAs (miR-19a-3p or miR-23a/27a/24-2 clus-
ter downregulation) can promote the activation of specific
signaling pathways, and the differentiation of a specific im-
mune cell type (M2 phenotype of TAMs) in the tumor
microenvironment.
Interestingly, miR-155 has been also reported to mediate
the antitumor potential of distinctive immune cell subsetsin breast cancer. In particular, miR-155 upregulation has
been recently demonstrated to be required in the myeloid
cell compartment for the promotion of antitumor immun-
ity in early stages of breast cancer carcinogenesis [98]. In a
spontaneous breast cancer model, specific miR-155 knock
down in myeloid cells is able to induce faster tumor
growth, reduction of M1-like TAMs and enrichment of
protumor cytokines within tumor milieu, all concurring to
create an immunosuppressive microenvironment [98]. In
particular, the proposed mechanism involves the regula-
tion of SHIP1, which is the main negative regulator of the
pro-inflammatory PI3K/AKT pathway. The inhibition of
this pathway was demonstrated to revert the common
pro-inflammatory and protumor events mediated by AKT
activation [99].
In the same direction, miR-126/126* pair has been
shown to have an antitumor role by inhibiting breast
cancer cell invasion and metastasis [100], either through
the direct targeting of stromal cell-derived factor-1 alpha,
SDF-1α, and with the indirect suppression of chemokine
(C-C motif) ligand 2, CCL2, in cancer cells. These two
chemokines mediate the sequential recruitment of two dif-
ferent non malignant cell types to primary tumor site:
SDF-1α is responsible for attraction of mesenchymal stem
cells (MSCs), while the second for inflammatory mono-
cytes. MSCs are supposed to create a paracrine loop with
cancer cells to induce cell invasion and migration, mean-
while monocytes act to promote the extravasation of
tumor cells [101, 102]. Therefore, miR-126/126* pair is
able to modulate the composition of the microenviron-
ment of primary tumors in order to contrast breast cancer
metastasis. These findings are perfectly in line with discov-
eries correlating reduced expression of miR-126 to poor
metastasis-free survival of breast cancer patients [103].
As previously described, the complexity of tumor
microenvironment includes innate immune components
recruited to eradicate latent cancer cells. Among them,
NK cells are a subset of lymphocytes that can rapidly
respond to the presence of tumor cells and initiate an
antitumor immune response. NK cells express receptors
through which they are capable to detect their targets
on cancer cells. MiR-20 has been demonstrated to regulate
NK cytotoxicity in ovarian cancer through the targeting of
MICA/B, a MHC class I chain-related molecules widely
expressed on epithelial tumor cells [104]. This protein is
recognized by NK cells through the NK group 2 member
D receptor (NKG2D), whose pathway is critical for direct
recognition of malignant cells by immune surveillance sys-
tem [105]. In vitro and in vivo studies have shown that
miR-20-mediated downregulation of MICA/B induced the
reduction of NKG2D recognition resulting in the dimin-
ished killing of malignant cells by NK compartment, thus
leading to enhanced tumor cell survival in vivo [106]. The
same mechanism has been demonstrated for miR-10b/
Table 2 Main deregulated microRNAs/targets, and the biological roles in immune- and cancer-related pathways in solid tumors
Cancer type miRNA Expression status and
cell localizationb
Target Immune-related role Cancer-related role Refc
Breast ↑miR-10b Cancer cells ↓MICB Suppression of NK-mediated killing of tumor
cells
Metastasis developmentd [107]
↑miR-19a-3p M2 Macrophages ↓FRA-1 Macrophage polarization Inhibition of cancer progression and
metastasis development
[95]
↑miR-21 Cancer cells ↓PIAS3 Reduced chemokine production and
lymphocyte migration, immunoresistance to
cancer immunotherapyd






M2 Macrophage polarization Xenograft tumor growth [97]
↓miR-126/126a Cancer cells ↑SDF-1α Downregulation of Ccl2 expression,
Suppression of Inflammatory monocyte
recruitment
Repression of MSC recruitment, lung
metastasis promotion
[100]
↓miR-146a Cancer cells ↑IRAK1 ↑TRAF6 Modulation of inflammationc Cell Invasion and Migration impairment
(NF-kB signaling block)
[92]
↑miR-155 Cancer cells ↓SOCS1 STAT3 signaling activation Cancer cell proliferation, colony
formation, and xenograft tumor growth
[141]





↓MEF2Cd Macrophage differentiationd Promotion of cancer cell invasion [163]
↑miR-494 MDSCs ↓PTEN Accumulation of MDSCs Tumor cell invasion and metastasis
development
[117]
Gastric ↓miR-146a Cancer cells ↑IRAK1 ↑TRAF6
↓IL8
Modulation of inflammationd Antitumor activity [146]
Ovarian ↑miR-20a Cancer cells ↓MICA/B Suppression of NK-mediated killing of tumor
cells
Long-term cellular proliferation, invasion
capabilities
[104]
↓miR-199a Cancer cells ↑IKKβ Cytokine production Tumor progression, chemosensitivity
(NF-kB signaling modulation)
[148]
↑miR-424 Cancer cells ↓PDL1
↓CD80
T cell activation Chemosensitivity [151]
Colorectal ↓miR-17-5p/
miR-20a/miR-124
MDSCs ↑STAT3 Inhibition of immunosuppressive potential
of MDSCs
Tumor growth [142–144]
↑miR-21/miR-29ba Cancer cells and
immune cells
↑IL-6 (Indirectly) Activation of pro inflammatory immune
cellsd





Cancer cells ↓MICA Suppression of NK-mediated killing of tumor
cells
Long-term cellular proliferation, invasion
capabilitiesd
[108]














Table 2 Main deregulated microRNAs/targets, and the biological roles in immune- and cancer-related pathways in solid tumors (Continued)
Melanoma ↓miR-34a/c Cancer cells ↑ULPB2 Suppression of NK-mediated killing of tumor
cells
Cell cycle arrest, senescence, apoptosis [111–112]
↓miR-17 T cells ↑STAT3 Impairment of T cell responsed Tumor growthd [142]
Melanoma and
Lewis lung cancer
↓miR-155 Immune cells ↑HIF1a Recruitment of MDSC cells to tumor
microenvironment
Promotion of tumor growthd [118]
Lung ↑miR-23a T cells ↓BLIMP1 Suppression of CD8+ T cell functiond Tumor progression, TGF-β-mediated
immune evasiond
[145]
Glioma ↓miR-124 T cells ↑STAT3 Impairment of T cell responses Tumor growth [143]
Various solid tumors ↓miR-29 Cancer cells ↑B7-H3 Inhibition of NK and T cell functiond Protumor activityd [114–115]
↓miR-214a Cancer cells and
CD4+CD25+ T cells
↓PTEN Expansion of Treg cells Promotion of tumor growth [166]
a Detailed mechanism involving microvesicles-cell interactions (see also subsection “MicroRNAs and cell-to-cell communication”)
b These data are referred to studies in either tissue samples or in vitro/in vivo models
c Reference number listed in bibliography
d Further investigation is needed
Upregulation of miRNA or miRNA target. Downregulation of miRNA or miRNA target
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miR-20a, miR-93, miR-106b/MICB pair in hepatocellular
cell lines [107, 108]. These data propose a miRNA-based
immune escape mechanism for tumor cells, which can
partially explain the correlation between overexpression of
these miRNAs and poor prognosis in cancer patients.
Similarly to human ovarian cancer cells, human
melanoma cells have been reported to express NKG2D re-
ceptor ligands such as MICA and ULBP2 [109]. Recently,
Heinemann A. et al. have identified serum ULBP2 overex-
pression as a strong independent predictor of poor
prognosis in melanoma patients [110]. The same group
also demonstrated that the tumor suppressor miR-34a/c
repressed ULBP2 expression by directly binding to the
3’-UTR [111]. Together with the fact that miR-34a/c
expression is frequently lost in cancer, these miRNAs
might be crucial for tumor immune surveillance [112].
This immuno-suppressive mechanism is also suggested
to predispose HBV-Positive hepatocellular carcinoma
(HBV-HCC) patients to the development of intrahepatic
venous metastasis. Specifically, miR-34a deregulation has
been linked to immune escape mechanism in HBV-HCC,
whose development is supposed to be associated with
HBV and HCV virus infection [113]. In particular, TGF-β/
miR-34a/CCL22 axis induced the recruitment of Treg cells
that are known to have an inhibitory role in the immune
system and, ultimately, to participate to escape immune
surveillance helping tumor cells [113]. Interestingly, TGF-
β signaling activation induces the suppression of miR-34a,
CCL22 expression and in turn recruitment of Treg cells in
liver microenvironment.
In the context of immune cell function regulation,
miR-29 has been identified as a negative regulator of B7-
H3 protein, which is a surface immunomodulatory
glycoprotein inhibiting NK and T cell functions [114].
Specifically, mir-29 and B7-H3 expression levels have
been found inversely correlated in both solid tumors and
cancer cell line experiments [115]. The downregulation
of miR-29 family members has been reported in many
cancers, where they influence cell proliferation, apop-
tosis and metastasis development through the modula-
tion of different targets [116]. Additional in vivo and
in vitro studies have to be performed in order to validate
the role of miR-29 in the promotion of antitumor im-
munity mediated by NK and T cell. Along with NK and
T cells, the expansion and function of MDSCs depend
on soluble factors released by tumor and stromal com-
partments and by activated immune cells [116]. Re-
cently, it has been demonstrated that two different
miRNAs, miR-494 and miR-155, are fundamental for the
recruitment of MDSCs to the tumor site, contributing to
the modulation of their immunosuppressive function
and to tumor growth in breast cancer and glioma
models, respectively [117, 118].MicroRNAs and cancer-related immune pathways in solid
tumors
Cancer and immune cells produce various growth or an-
giogenic factors, proteinases, chemokines and cytokines,
which contribute to removal of tumor cell or to the
formation of an immunosuppressive microenvironment
[119, 120]. In particular, the activation of specific transcrip-
tion factors and the presence of primary inflammatory cyto-
kines represent key connection elements between immune
and cancer cells [121, 122]. Among them, nuclear factor
kappa-B (NF-kB), transducers activator of transcription 3
(STAT3), tumor necrosis factor (TNF) and transforming
growth factor β (TGF-β), have been demonstrated to medi-
ate the activation of numerous oncogenic pathways [122–
124]. NF-kB is a major regulator of inflammation and in-
nate immunity, and its aberrant regulation has been de-
scribed in many human tumors [124]. Different upstream
stimuli have been identified to trigger NF-kB pathway, in-
cluding pro-inflammatory cytokines (e.g. TNF-α, IL-1β)
and microorganism infections (bacterial and viral infec-
tions), which both determine the activation of the IkB kin-
ase (IKK) complex. This protein unit phosphorylates
inhibitor of NF-kB and allows the translocation of NF-kB
into nucleus [125]. The downstream effects of NF-kB are
cell-type dependent, consisting in induction of gene ex-
pression related to pro-inflammatory signals in inflam-
matory cells and of anti-apoptotic genes in tumor cells,
favoring tumor development [125]. One of the most
important activators of NF-kB signaling is TNF-α, which
binds to its specific receptor expressed by immune or can-
cer cells [126]. This pro-inflammatory cytokine has been
also demonstrated to exert tumor–promoting activities,
including promotion of angiogenesis and metastasis [127].
Similar to NF-kB, STAT3 is constitutively activated in
both tumor and immune cells increasing tumor cell prolif-
eration, survival and invasion and is activated by NFkB-
induced genes such as Interleukin 6 (IL6) [128–129]. On
the contrary, STAT3 signaling is required for immunosup-
pressive and pro-tumorigenic functions of immune cells of
both innate (MDSCs, TAMs) and adaptive system (Treg,
Th17), opposing the role of NF-kB in favoring antitumor
immune response [130, 131]. Immunosuppressive and
anti-inflammatory signals derive also from the action of
TGF-β, which attenuates the production of pro-
inflammatory cytokines [132]. Furthermore, TGF-β is
known to be a key cytokine during carcinogenesis, be-
ing secreted and upregulated in a wide range of tumors
[133–136]. Therefore, different signaling represent crucial
pathways in the model of origin of cancer-related inflam-
mation and large body of literature supports the central
role of miRNAs as both down- or up-stream modulators
of the activation of these factors (Table 2).
Among these miRNAs, miR-21 and miR-155 have
been found to be part of the complex immune regulatory
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two oncomiRNAs are linked in different ways to the con-
stitutive activation of STAT3 pathway, promoting the ex-
pression of immunosuppressive factors and thus having
immune suppressive effects. Inhibition of miR-21 expres-
sion levels in MCF7 cell line has recently been reported to
increased chemokine and lymphocyte migration, which is
paralleled to an increase in levels of PIAS3, an inhibitor of
activated STAT3, and of STAT3 phosphorylation, making
miR-21 a good therapeutic target [137]. In particular, this
mechanism is explained by the activity of miR-21, which
inhibits the release of RANTES and IP-10, T cell chemoat-
tractants, through the targeting of PIAS3 [137]. These
data have demonstrated a positive relationship between
miR-21 and STAT3 in a tumor cell line context, as previ-
ously reported [138, 139]. In addition to the protumor ac-
tivities affecting cell survival and proliferation, miR-21/
STAT3 network could contribute to create an immune
suppressive tumor milieu, thus supporting the miRNA
role as regulator of drug resistance [140]. Similarly to this
miRNA, miR-155 exerts its oncogenic role by negatively
regulating the tumor suppressor gene of cytokine signaling
1 (Socs1) and consequently promoting cell proliferation,
colony formation and xenograft tumor growth in breast
cancer model [141]. The immunomodulating property is
represented by the constitutive activation of STAT3 sig-
naling as tumor promoting inflammatory mechanism.
Other miRNAs have been linked to the regulation of
STAT3 signaling. As previously described, effective adap-
tive immune responses have a key role in contrasting
tumor progression and different immune cell subsets
contribute to maintain this potential. In this context,
STAT3 mRNA has been demonstrated to be directly tar-
geted by miR-17-5p, miR-20a and miR-124 in different
cancer models where forced miRNA upregulation has
been showed to sustain T cell response in favor of an
antitumor activity [142–144]. Conversely, miR-23a
contributes in suppressing CTL function, at least in a
murine model of lung cancer [145]. Specifically, the
TGF-β-mediated upregulation of miR-23a in CTL cells
induced a tumor immune-evasion mechanism by targeting
the transcription factor BLIMP-1, in turn promoting
tumor progression [145].
As previously mentioned, miR-146a is a miRNA in-
volved in the control of both inflammatory response to
infection and of innate immune system. In particular it
has been described as a NF-kB-dependent gene, which
in turn downregulates the expression of immune target
genes, such as IRAK1 and TRAF6 (two adaptor molecules
downstream of toll-like and cytokine receptors), and re-
presses NF-kB signaling in LPS-stimulated monocytes
[83]. MiR-146a axis has been investigated also in gastric
cancer cells, where a link between miR-146a and the in-
flammatory response to Helicobacter pylori has beenenvisaged [146]. Similarly, forced ectopic expression of
miR-146a in MDA-MB-231 breast cancer cell line inhibits
endogenous NF-kB expression and activity through
IRAK1 and TRAF6 targeting, reducing their metastatic
potential [147]. Further investigations are needed in order
to fully elucidate how miR-146a contribute to tumor
development.
A study by Chen R. et al. has described a similar miR-
199a/IKKβ/NF-kB axis also in epithelial ovarian cancer
cells (EOCs) [148]. MiR-199a has been identified as a
negative regulator of IKKβ mRNA, which encodes for
the β subunit of IKK, the direct upstream activator of
NF-kB pathway [149]. In EOCs, IKKβ contributes to a
pro-inflammatory environment by functionally inducing
NF-kB pathway through the activation of Toll-like re-
ceptor 4 (TLR4)-MyD88 signaling sustaining tissue re-
pair processes and the secretion of pro-inflammatory
signals [150]. Consequently, EOC cells are induced to se-
crete pro-inflammatory/protumor cytokines, including
IL-6, IL-8, MCP-1, MIP-1α, RANTES, GRO-α, GM-CSF
and MIF. MiR-199a targets IKKβ resulting in the inhib-
ition of NF-kB signaling. Therefore, the loss of this anti-
inflammatory miRNA may be an important step that
contributes to tumor progression. These data may have
important implications in tissue repair, tumor progres-
sion and chemoresistance. Interestingly, chemosensitivity
of EOCs has been shown to be restored by miR-424
overexpression, which activates T cell immune response
through direct targeting of critical immune checkpoints,
such as the programmed death-ligand 1 (PD-L1) and
CD80 [151].
MicroRNAs and cell-to-cell communication
miRNAs have emerged as crucial mediators of intercellu-
lar communication occurring between immune and tumor
cells within the tumor microenvironment [152]. The vast
majority of studies described the mechanisms of deregula-
tion of endogenous miRNAs in immune or tumor cells,
which can modulate the cancer-related immune response,
thus also affecting tumor progression. More recently, a
mechanism of indirect cell-to-cell communication has
been described, showing that exogenous miRNAs can be
transferred from a donor to a recipient cell in order to
modulate gene expression [21]. This process is based on
cell-derived extracellular vesicles (EVs) containing both
proteins and RNAs, including miRNAs and mRNAs. Gen-
erally EVs are subdivided into three major classes of parti-
cles according to size, ectosomes or shedding vesicles
(200–1000 nm) and exosomes (30–200 nm), which differ
from apoptotic bodies (0.5–3 μm) that derive from cells in
apoptosis or under stress [153]. In particular, exosomes
have been identified as the most important carriers of
functional miRNAs [21]. Exosomes are small membrane-
derived vesicles of endocytic origin, which can be released
Paladini et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:103 Page 12 of 19by different types of cell, including immune and tumor
cells, under both normal and pathological conditions
[154]. The mechanism of horizontal exchange of exosome
containing miRNAs between cells is described in Fig. 2.
Interestingly, the composition of RNA molecules in
exosomes is different from the content of cell of origin
suggesting the existence of not well defined active
mechanisms for sorting specific RNAs into exosomes
[155–157]. In particular, the ESCRT (endosomal sorting
complex required for transport) protein complex is likely
to be involved in some of these processes [157–159].
However, the exact nature of these mechanisms remain to
be extensively characterized. The transfer of this genetic
information can alter gene expression in neighboring and
even distant cells. Recent data have demonstrated involve-
ment of exosome at different levels, including immune re-
sponses and cancer [160–162]. These findings suggested
that exosome-mediated miRNA transfer between immune
and tumor cells could be crucial to identify new miRNAs
as modulators of tumor microenvironment and potential
target for cancer immunotherapy. Several recent studies
provided evidences of this hypothesis (Table 2). A study
by Yang M. et al. firstly demonstrated that after transfec-
tion into IL-4 activated M2 macrophages, the exogenous
miR-223 can shuttle into co-cultivated breast cancer cellsFig. 2 Mechanisms of RNA transfer in cell-to-cell communication. Mechani
based on two systems, vesicle- and protein-mediated transport. (1,2,3) After e
cell by (1) the fusion of the exosome with the recipient cell membrane, by (2)
molecules can be exported and transported out of the cells by microvesicles
protein complexes (violet boxes) including Argonaute, NPM1 and HDL pr
(6) transporter-mediated release (ABCA1) and are translocated to target c
in the delivery of microRNA or mRNA molecules to the cytosol of the rec
regulation. E: Endosome; EE: Early Endosome; G: Golgi; L: Lysosome; MVB:from M2-derived exosomes containing miRNA. Inter-
estingly, exosome–transferred miR-223 stimulates the
invasive behavior of breast cancer cells by targeting of
Mef2c/β-catenin pathway, thus leading to increase cell
migration [163]. A more complex regulatory loop between
cancer and immune cells has been described in in vitro co-
culture model of colorectal cancer: the secretion of IL-6
from immune cells promotes invasiveness of cancer cells,
which in turn induces immune-related IL-6 production and
miR-21 release through the tumor-derived secretion of
miR-21 and miR-29b in the tumor microenvironment
[164]. As result, this mechanism mediated by exogenous
miRNAs is suggested to be able to support the maintenance
of a pro-tumorigenic inflammatory environment. Moreover,
the two tumor-secreted miR-21 and miR-29b have been re-
ported to act as ligands binding to receptors of TLR family
of macrophages, producing pro-inflammatory signals in the
tumor microenvironment and pro-metastatic potential in
in vivo models [165]. Similarly, miR-214 has been identified
as another tumor-secreted miRNA capable to support sim-
ultaneously host immune suppression and tumor growth in
in vivo mice models [166]. Specifically, tumor-derived miR-
214 was delivered into peripheral CD4+ T cells and found
to induce Treg expansion by targeting phosphatase and ten-
sin homolog (PTEN) protein. The secretion of higher levelssms underlying the transfer of RNA molecules between cells are mainly
xosome release from donor cell, RNA content is delivered into recipient
phagocytosis- or (3) endocytosis-like internalization of the exosome. RNA
also as (4) shedding ectosomes or (5) apoptotic bodies. (6,7) Different
oteins, bind miRNAs and are transferred out of the cell through
ell by (7) receptor-mediated uptake (SR-B1). All these pathways result
ipient cell where they may contribute to post translational gene
Multivesicular Bodies; N: Nucleus; P: Protein; UP: Undigested Protein
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to promote tumor growth in nude mice [167]. The dual
role of tumor-derived exosomes in the modulation of im-
mune responses and in the mediation of tumor progression
has been also investigated at circulating level in cancer pa-
tients [167–170]. In particular, higher level of circulating
exosomes have been found in breast or ovarian cancer pa-
tients compared to healthy individuals, and serum exo-
somes derived from patients with oral or ovarian cancer
have been characterized as inhibitors of T cell functions
[167–170]. In this context, interestingly circulating tumor-
derived exosomes isolated from serum of nasopharyngeal
carcinoma patients have been characterized as miRNA-
enriched vesicles able to impair in vitro T cell function
interfering with ERK and STAT signaling pathways in T
cells [171]. In addition to the exosome mediation, miRNA
transfer has been demonstrated to happen directly via
intercellular contact through gap junctions. Specifically,
human macrophages have been reported to be able to se-
crete miR-142 and miR-223, which are transferred into
hepatocarcinoma cells (HCCs) [172]. These miRNAs
affect posttranscriptional regulation of target proteins in
HCC cells, in particular inducing decreased expression
levels of stathmin-1 (STMN1) and insulin-like growth
factor-1 receptor (IGF-R1), and, importantly, inhibiting
proliferation of cancerous cells in in vitro experiments
[172]. In opposition to its antitumor role in HCC model,
M2-derived miR-223 has been previously shown to
stimulate proliferation in breast cancer cells because of
the targeting of Mef2c/β-catenin pathway related to the
inhibition of cell migration [163, 173, 174].
More data regarding different mechanisms of miRNA
transfer from non-immune stromal to tumor cells have
been published [175]. All these findings highlight the po-
tential role of shuttled miRNAs in mechanisms used by
cancer cells to evade immunosurveillance and to sustain
tumor progression.
MicroRNA-based immune response as potential
target for anticancer immunotherapies
The potential of miRNAs in regulating different cellular
pathways and as mediators of interactions between cells
make them ideal drug targets. Indeed, different local and
systemic delivery strategies are already under investigation
[176]. Their ultimate aim is either enhancing or inhibiting
the expression of specific miRNAs acting as tumor sup-
pressor genes or oncogenes, respectively [176]. These ef-
fects can be achieved by targeting miRNAs at different
levels of their biogenesis and activity (Fig. 3). In the con-
text of cancer cell targeting, promising results have been
obtained with the use of miRNA antagonists and miRNA
mimics in preclinical studies [177, 178]. miRNA antago-
nists are single-stranded oligonucleotides complementary
to miRNA sequences, designed to target and functionallyreduce miRNA activity [179]. On the other hand, restor-
ation of tumor suppressor miRNA level is obtained by the
delivery of chemically synthesized short double-stranded
oligonucleotides, which functionally mimic pre-miRNA
duplexes [180]. To date, these two strategies are under in-
vestigation in clinical trials based on targeting of miR-122
and miR-34a for the treatment of hepatitis C virus and
advanced HCC, respectively [181]. Due to the recent
advances in the understanding of specific miRNA mod-
ulatory mechanisms that influence the immune system
and tumor-mediated immunity, researchers are now
developing novel miRNA-based interventions for cancer
immunotherapy. Currently, different immunotherapies
have been approved aimed to activate antitumor im-
munity, including passive immunization with monoclonal
antibodies, systemic delivery of cytokines and addition of
immune adjuvants into the tumor microenvironment
[182]. Among them, the use of tumor targeting monoclo-
nal antibodies seems to be the most promising approach
for some hematologic and solid tumors [183]. Novel
antibody-based approaches are under development in
order to block immunosuppressive networks or stimulate
antitumor cytotoxicity [184–188]. In this context, the
regulation of cancer-related immune responses through
the fine tuning of immune-related miRNA expression
could contribute to enhance antitumor immunity and at
the same time inhibit tumor development. Interestingly,
miRNAs can be targeted not only in cancer cells but also
in stromal cells, such as tumor-associated fibroblasts and
lymphocytes, which are essential for tumor formation,
progression and metastasis. In this case, successful deliv-
ery directed to specific tissue and cell, represents a big
challenge for in vivo miRNA-mediated immunomodula-
tion. Different types of vehicles have been synthesized as
biodegradable and biocompatible carriers of miRNA
mimics and miRNA antagonists, including liposomes,
polymers, nanoparticles and viral agents [182]. The ver-
satility of liposomal carriers have made them suitable
elements for designing of co-delivery system of miRNAs
and small-molecule drugs which concurrently are able to
target the same cancer cell resulting in an effective synergic
antitumor effect. Firstly employed for small conventional
drugs and siRNA delivery in clinical trials, liposomal for-
mulation of miR-34a mimic is currently used in a Phase I
clinical trial of patients with advanced HCC [17]. Polymeric
micelles, polymeric nanoparticles and carbon nanomaterials
have already been employed in co-delivery system of
different miRNAs and chemotherapeutics in different
tumor models [189–192]. Interestingly, systematic intensive
infiltration of myeloid leukocytes in solid tumors and their
enhanced endocytic activity make these cells the ideal tar-
gets for nanocomplex-mediated delivery. Accordingly, a re-
cent work has obtained the induction of miR-155 activity
selectively in DCs in ovarian cancer microenvironment
Fig. 3 MicroRNA-based strategies for anti-cancer therapy. The main strategies for the modulation of miRNA activity are basically based on
enhancing or inhibiting the expression of specific miRNAs with miRNA mimics (1) or miRNA antagonists (2), respectively. Modified miRNA
molecules have been developed to increase the stability of miRNA mimics and miRNA antagonists, including miRNA mimics containing
modified cyclopentyl-guanine based, cholesterol-conjugated 2′-O methyl-modified miRNA mimics/anti-miRs, locked nucleic acid (LNA)-
modified anti-miRs and 2′-O-methoxyethyll-4′-thioRNA (MOE-SRNA). A different approach consists in miRNA sponges (3), which are complex
constructs able to interfere with miRNA/mRNA interaction. Interference at miRNA biogenesis level is obtained with small-molecule inhibitors
of miRNAs, SMIRs (4). Modified or unmodified miRNA modulators can be delivered to target cells by using viral (5) or non-viral vectors consisting in
different types of biocompatible and biodegradable nanoparticles (6)
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T-cell mediated protective immunity and therefore antitu-
mor responses [193]. In the same context, downregulation
of miR-31/miR-214 and upregulation of miR-155 are cap-
able to selectively reprogram normal human fibroblasts into
tumor-promoting cancer-associated fibroblasts (CAFs)
[194]. Furthermore, downregulation of miR-214 has also
been demonstrated to directly influence chemokine (C-C
motif) ligand 5 CCL5 production, whose increased levels
lead to enhanced tumor growth, by stimulating OvCa cells
invasion [195]. Therefore, miR-31/miR-214 restoration and
inhibition of miR-155 in protumor CAFs could beconsidered as potential immunotherapeutic options for
ovarian cancer. Similarly, miR-21 has been identified as a
potential immunotherapeutic target for its ability to
positively regulate STAT3 signaling, which is a prerequisite
for effective T cell therapy. In addition, miR-21 can suppress
T cell priming and impair responses triggered by anti-
mycobacterial vaccination [196].
Opposed to previous described non-viral delivery ap-
proach, viral vectors have been investigated as potential
carriers of miRNAs in order to improve the efficiency
and the specificity of the systemic delivery. Different ex-
amples of application of virus can be mentioned, starting
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with the potential of reducing tumor-infiltrating MDSCs
and their protumor activity in in vivo breast cancer
model [117]. Lentiviruses are able to integrate their re-
versed DNA into human cells, implicating the potential
risk of different oncogenic pathways’ activation. Adeno-
virus and adeno-associated virus are more suitable for
therapeutic purposes, due to their non-integrative activ-
ity [197]. However, the general increased immunogenic
microenvironment and the limits in their large-scale
production make viral vectors a less safe delivery system
than non-viral approach.
In the context of extracellular vesicle-based therapy,
the identification of exosomes as miRNA carriers and
mediators of communication between cells of tumor
microenvironment constitutes an opportunity to study
new targeted approaches [198]. Similar applications have
been already investigated using tumor-derived EVs to
deliver a therapeutic miRNA to breast cancer cells with
specific phenotypes [199]. In particular, the tumor sup-
pressor miRNA let-7a has been efficiently delivered to
epidermal growth factor receptor (EGFR)-expressing
breast cancer cell, exerting the in vivo inhibition of
tumor development. The specific targeting of receptor-
expressing cells was obtained by using exosomes derived
from engineered donor cells with EGFR ligand on plasma
membrane. As regards the immune system, EVs derived
from immune and non-immune cells are able to positively
and negatively regulate the immune response [200]. Thus,
cell-derived exosomes containing immune-related miR-
NAs could have the potential to be used as therapeutic
agents to enhance immunostimulatory signaling pathways
and antitumor immunity. In this context, tumor-derived
exosomes has been primarily investigated, showing their
potential to concur to immune evasion [201, 202]. Re-
cently, miRNAs have been reported to be associated with
the RISC-Loading Complex in breast cancer-derived exo-
somes [203]. These entities display cell-independent
miRNA biogenesis able to sustain Dicer-dependent mRNA
targeting in recipient cells. Specifically, cancer exosomes
can induce malignant transformation of normal epithelial
cells in a Dicer-dependent manner. This work contributes
to propose miRNA-containing exosomes as active players
of cancer progression. However, the use of exosomes as
carriers of miRNAs in cancer therapies is only at the be-
ginning and needs to be further investigated.
Conclusions
The importance of specific miRNAs for immune cell de-
velopment and function has been widely demonstrated,
and their association with different human diseases is a
matter of fact. Alteration in levels of these immune-
related miRNAs could determine the modulation of im-
mune pathways and the crosstalk between cells in thetumor microenvironment, thus resulting in a non-effective
cancer-related immune response. Altogether, these findings
suggest the development of novel miRNA-based ap-
proaches directed to target immunomodulatory mecha-
nisms. Reported data have also highlighted that miRNAs
can exert their function in a cell type context-dependent
manner. Thus, the design of more effective in vivo
strategies of miRNA delivery needs to be improved, in
particular focusing on enhancing tissue and cell specificity
of miRNA vectors. Accordingly, exosome- and immune
cell-based delivery represent two interesting potential
strategies for miRNA-based cancer immunotherapy. In
addition, the surface of carrier vesicles can be specifically
modified with ligands or antibodies which are able to bind
to the endogenous receptors of tumor or stromal cells.
Therefore, the characterization of the tumor microenvir-
onment in terms of miRNA/mRNA expression and their
localization at cellular level is crucial. In addition, the
mechanisms of miRNA-based modulation of immune
responses need to be investigated in relation to differ-
ent immunomodulatory therapies. In this context, the
combination of miRNA-related immunotherapy with
conventional cytotoxic drug agents or targeted therapy
could represent a valuable opportunity for effective
therapeutic interventions in human cancer.Abbreviations
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